Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at 2024 SAPA Scientific Symposium

2024-04-10
|
Page View:

1.png

2024 SAPA Scientific Symposium
Innovation with Versatility: New Approaches from Benchtop to Bedside
The 2024 Scientific Symposium, a flagship event of the Sino-American Pharmaceutical Professionals Association (SAPA), will be held in-person on April 20th at Rutgers Robert Wood Johnson Medical School. The early bird registration deadline is extended to April 8th. The theme of this year's symposium is "Innovation with Versatility: New Approaches from Benchtop to Bedside". 

During the SAPA Scientific Symposium, Dr. Qingcong Lin, President of Medicilon USA Corp. will give a wonderful presentation "Oncology and Other Disease Models to Facilitate Drug Candidate Selection and IND filing".
Medicilon boasts ~400 tumor animal models and ~230 non-tumor animal models. Keeping pace with industrial development and market demand, Medicilon's experienced Pharmacology and Pharmacodynamics Department has established a complete animal model library based on verification, precise and efficient drug efficacy testing. The test subjects we provide include non-human primates, dogs, rats, mice, rabbits, guinea pigs, and miniature pigs. 
At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal, double, polyclonal), siRNA and AAV.
Date: April 20th, 2024 (9:00 am - 5:00 pm EST)
Location: Rutgers Robert Wood Johnson Medical School (675 Hoes Lane West, Piscataway, NJ 08854)

3.png

Meet with Medicilon
Subject丨APPLIED PHARMACEUTICAL TOXICOLOGY (APT) 2024

Share:
Return
Relevant newsRelevant news